DXCM - Dexcom Inc - SEC Form 4 Insider Trading Screener

Manufactured Goods - Specialty Instruments - Surgical & Medical Instruments & Apparatus - DXCM (1093557)
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
Real-time CSV, Options, Alerts
100 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
S24+0+2-3+0

X

Filing Date

Trade Date

Ticker

Insider Name

Insider Title

Trade Type 

Price

Qty

Owned

ΔOwn

Value

1d

1w

1m

6m

2018-09-14
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$145.17-5,00088,105-5%-$725,851
2018-09-11
DXCMBlackford Quentin S.EVP, CFO, PFO, PAOS - Sale$147.04-8,44087,131-9%-$1,241,028
2018-09-10
DXCMMoy JeffreySVP, OperationsS - Sale$143.53-10,33063,245-14%-$1,482,667
2018-09-10
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$143.75-5,48387,634-6%-$788,210
2018-09-10
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$143.75-5,58793,105-6%-$803,160
2018-09-10
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$143.75-5,483116,974-4%-$788,210
2018-09-10
DXCMMurphy Patrick MichaelVP, Legal Aff, Chf Compl OfcrS - Sale$143.69-2,37231,308-7%-$340,825
2018-09-10
DXCMLeach Jacob StevenSVP, Research, DevelopmentS - Sale$143.75-4,614153,708-3%-$663,286
2018-09-10
DXCMAce Heather SSVP HRS - Sale$143.75-1,83269,339-3%-$263,360
2018-09-10
DXCMAbbey DonaldEVP, Quality, Regulatory AfrsS - Sale$143.75-2,30398,639-2%-$331,068
2018-09-10
DXCMBlackford Quentin S.EVP, CFO, PFO, PAOS - Sale$143.75-7,14995,571-7%-$1,027,706
D
2018-09-10
DXCMSayer Kevin RPres, CEO, COBS - Sale+OE$143.62-25,495320,837-7%-$3,661,573
2018-08-24
DXCMAltman Steven RDirS - Sale$136.47-5,00061,304-8%-$682,359
2018-08-24
DXCMFoletta Mark GDirS - Sale$137.50-1,00021,147-5%-$137,503
D
2018-08-24
DXCMLeach Jacob StevenSVP, Research, DevelopmentS - Sale+OE$138.32-20,577158,302-12%-$2,846,155
2018-08-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$140.03-2,58492,912-3%-$361,833
2018-08-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$139.96-3,114122,457-2%-$435,843
2018-08-14
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$124.25-5,00098,567-5%-$621,253
D
2018-08-13
DXCMSayer Kevin RPres, CEO, COBS - Sale+OE$123.22-11,161335,171-3%-$1,375,211
2018-08-10
DXCMMurphy Patrick MichaelVP, Legal Aff, Chf Compl OfcrS - Sale$124.19-12,50033,680-27%-$1,552,310
2018-08-06
DXCMAugustinos NicholasDirS - Sale$121.33-12,30022,164-36%-$1,492,381
2018-08-01
DXCMMoy JeffreySVP, OperationsS - Sale$94.13-5,83173,572-7%-$548,872
2018-07-25
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$101.91-3,114125,571-2%-$317,335
2018-07-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$102.48-2,58195,496-3%-$264,513
2018-07-16
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$99.56-5,000103,567-5%-$497,816
2018-07-16
DXCMGregg Terrance HExec COBS - Sale$99.56-10,000504,017-2%-$995,561
2018-07-09
DXCMSayer Kevin RPres, CEOS - Sale$99.79-14,219335,171-4%-$1,418,856
2018-06-28
DXCMMoy JeffreySVP, OperationsS - Sale$92.48-59,19379,403-43%-$5,474,297
2018-06-25
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$98.58-2,58198,077-3%-$254,431
2018-06-15
DXCMGregg Terrance HExec COBS - Sale$97.81-10,000514,017-2%-$978,096
2018-06-12
DXCMTopol EricDirS - Sale$100.10-20,00088,257-18%-$2,001,998
2018-05-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$86.00-2,581100,658-3%-$221,963
2018-05-15
DXCMGregg Terrance HExec COBS - Sale$85.90-10,000524,017-2%-$858,974
D
2018-05-14
DXCMSkyler Jay SDirS - Sale+OE$88.00-30,00036,810-45%-$2,640,000
DM
2018-05-08
DXCMLeach Jacob StevenSVP, Research, DevelopmentS - Sale+OE$84.87-13,168158,478-8%-$1,117,567
D
2018-05-09
DXCMSayer Kevin RPres, CEOS - Sale+OE$84.37-17,245349,390-5%-$1,454,992
D
2018-05-08
DXCMSkyler Jay SDirS - Sale+OE$85.11-31,46436,810-46%-$2,678,024
2018-04-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$73.09-2,581103,239-2%-$188,649
2018-04-16
DXCMGregg Terrance HExec COBS - Sale$73.04-10,000534,017-2%-$730,414
2018-03-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$68.44-2,581105,820-2%-$176,643
2018-03-15
DXCMGregg Terrance HExec COBS - Sale$65.51-10,000544,017-2%-$655,122
2018-02-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$56.32-1,63879,021-2%-$92,252
2018-02-15
DXCMGregg Terrance HExec COBS - Sale$55.91-10,000516,902-2%-$559,095
2018-01-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$54.67-1,63580,659-2%-$89,384
2018-01-16
DXCMGregg Terrance HExec COBS - Sale$56.86-10,000526,902-2%-$568,588
2017-12-26
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$56.39-1,63582,294-2%-$92,204
2017-12-12
DXCMSayer Kevin RPres, CEOS - Sale$58.85-6,000280,826-2%-$353,092
2017-12-11
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$61.23-3,24579,547-4%-$198,691
2017-11-29
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$60.12-2,90096,426-3%-$174,340
2017-11-29
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$60.00-6,49082,792-7%-$389,400
2017-11-27
DXCMFoletta Mark GDirS - Sale$54.95-2,50018,095-12%-$137,386
2017-11-24
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$55.53-1,63583,929-2%-$90,788
2017-11-20
DXCMSayer Kevin RPres, CEOS - Sale$55.00-12,000286,826-4%-$660,000
2017-11-20
DXCMKahn BarbaraDirS - Sale$54.58-3,00027,448-10%-$163,727
2017-11-07
DXCMAltman Steven RDirP - Purchase$50.01+25,00062,855+66%+$1,250,250
2017-11-06
DXCMAltman Steven RDirP - Purchase$49.61+10,00037,855+36%+$496,100
2017-10-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$44.82-1,63585,564-2%-$73,274
2017-09-25
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$69.77-1,63587,199-2%-$114,080
2017-09-25
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$69.81-1,45099,326-1%-$101,219
2017-09-20
DXCMSayer Kevin RPres, CEOS - Sale$69.34-6,000298,826-2%-$416,044
2017-09-11
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$72.27-3,24489,282-4%-$234,441
2017-08-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$75.26-3,987108,087-4%-$300,045
2017-08-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$75.26-1,63596,180-2%-$123,053
2017-08-11
DXCMSayer Kevin RPres, CEOS - Sale$69.77-6,000320,680-2%-$418,637
2017-08-10
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$71.18-3,24499,989-3%-$230,921
2017-07-24
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$69.47-1,450112,074-1%-$100,725
2017-07-12
DXCMSayer Kevin RPres, CEOS - Sale$71.86-6,000326,680-2%-$431,174
2017-07-10
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$71.55-3,200103,233-3%-$228,972
2017-06-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$78.22-3,18797,815-3%-$249,273
2017-06-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$78.19-1,450113,524-1%-$113,378
2017-06-12
DXCMBalo Andrew KEVP, Clinical, RegulatoryS - Sale$69.06-3,200106,433-3%-$220,989
2017-06-12
DXCMSayer Kevin RPres, CEOS - Sale$69.07-6,000332,680-2%-$414,411
2017-05-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$68.24-1,450114,974-1%-$98,949
2017-05-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$68.29-3,182101,002-3%-$217,290
D
2017-05-17
DXCMSayer Kevin RPres, CEOS - Sale+OE$68.39-8,649338,680-2%-$591,525
2017-05-10
DXCMBalo Andrew KEVP, Clinical, RegulatoryS - Sale$71.93-3,200109,633-3%-$230,176
2017-04-24
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$75.89-1,450117,424-1%-$110,041+3+8
2017-04-24
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$75.78-3,182104,184-3%-$241,131+3+8
2017-04-20
DXCMGregg Terrance HExec COBS - Sale$74.10-15,000506,902-3%-$1,111,5000+4
D
2017-04-17
DXCMSayer Kevin RPres, CEOS - Sale+OE$75.63-10,000343,680-3%-$756,317+2+1
2017-04-10
DXCMBalo Andrew KEVP, Clinical, RegulatoryS - Sale$78.19-3,200112,833-3%-$250,208-1-3-10
2017-03-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$76.25-3,987118,874-3%-$304,006+1+3-10
2017-03-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$76.38-3,182107,366-3%-$243,029+1+3-10
2017-03-22
DXCMRoper JessSVP, CFOS - Sale$75.97-2,00054,949-4%-$151,937+1+3-10
D
2017-03-17
DXCMSayer Kevin RPres, CEOS - Sale+OE$77.82-10,000343,680-3%-$778,158+1+9-3
2017-03-14
DXCMKahn BarbaraDirS - Sale$77.36-3,00026,095-10%-$232,080+2-1-2
DM
2017-03-09
DXCMLeach Jacob StevenSVP, Research, DevelopmentS - Sale+OE$77.63-21,317144,255-13%-$1,654,8880-1-1
2017-03-13
DXCMValdes Jorge ACTOS - Sale$77.74-14,40044,521-24%-$1,119,5140+30
2017-03-10
DXCMBalo Andrew KEVP, Clinical, RegulatoryS - Sale$77.71-3,200116,033-3%-$248,6720+30
D
2017-03-09
DXCMLister JohnGM, EMEAS - Sale+OE$77.67-3,00084,034-3%-$233,002-1-1+1
D
2017-03-06
DXCMSkyler Jay SDirS - Sale+OE$78.13-31,89032,257-50%-$2,491,572-1-1+2
2017-02-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$78.42-3,18296,315-3%-$249,530+1+3+5
2017-02-22
DXCMRoper JessSVP, CFOS - Sale$78.76-2,33366,428-3%-$183,759+1+3+5
D
2017-02-17
DXCMSayer Kevin RPres, CEOS - Sale+OE$81.62-10,000299,391-3%-$816,177-1-1-2
D
2017-02-10
DXCMBalo Andrew KEVP, Clinical, RegulatoryS - Sale+OE$79.30-3,200103,872-3%-$253,760+3-1-5
D
2017-02-09
DXCMLister JohnGM, EMEAS - Sale+OE$79.73-3,00070,598-4%-$239,204+1+2-3
D
2017-02-09
DXCMValdes Jorge ACTOS - Sale+OE$79.76-7,00075,833-8%-$558,316+1+2-3
D
2017-02-01
DXCMValdes Jorge ACTOS - Sale+OE$80.00-13,90075,833-15%-$1,112,000-2-3-4
2017-01-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$79.50-3,18299,497-3%-$252,978-2-2-4
D
2017-01-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale+OE$79.99-9,637110,409-8%-$770,908-2-2-4
AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top